FLT3 and acute myeloid leukemia: Metabolomics studies (53–55) have been focused on the FLT3-mutant cells treated by FLT3 inhibitors, but here we demonstrated the effectiveness of AC220, particularly in combination with IACS-010759, on wild-type AML cells.